AVXL vs. MOR, TWST, VCEL, CPRX, MLTX, MRUS, BEAM, IBRX, ARWR, and HCM
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include MorphoSys (MOR), Twist Bioscience (TWST), Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Beam Therapeutics (BEAM), ImmunityBio (IBRX), Arrowhead Pharmaceuticals (ARWR), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Anavex Life Sciences vs.
Anavex Life Sciences (NASDAQ:AVXL) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
Anavex Life Sciences has higher earnings, but lower revenue than MorphoSys. Anavex Life Sciences is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Anavex Life Sciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Anavex Life Sciences' return on equity of -37.50% beat MorphoSys' return on equity.
31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Anavex Life Sciences currently has a consensus target price of $44.00, suggesting a potential upside of 426.95%. MorphoSys has a consensus target price of $18.25, suggesting a potential downside of 3.74%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than MorphoSys.
Anavex Life Sciences has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
Anavex Life Sciences received 414 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 74.79% of users gave Anavex Life Sciences an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
In the previous week, Anavex Life Sciences had 12 more articles in the media than MorphoSys. MarketBeat recorded 12 mentions for Anavex Life Sciences and 0 mentions for MorphoSys. Anavex Life Sciences' average media sentiment score of 0.90 beat MorphoSys' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.
Summary
Anavex Life Sciences beats MorphoSys on 14 of the 18 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:AVXL) was last updated on 2/22/2025 by MarketBeat.com Staff
